Sign inJoin waitlistJoin the waitlist

Kristin Bixel

Director, Gynecologic Oncology Clinical Research Group · Stanford Health Care

Credentials: · · · · ·

History

Gynecologic Oncology Clinical Research Group · Stanford Health Care
Present
Stanford Health Care
Present
Stanford Health Care
Present

Ohio State University College of Medicine
2014–2017
Obstetrics and Gynecology
Beth Israel Deaconess Medical Center
2009–2013
University of California at San Francisco School of Medicine (2009) CA
2005–2009

Research

Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study
Journal of Clinical Oncology · 2020 · 142 citations
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer
Journal of Clinical Oncology · 2016 · 108 citations
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target
Oncogene · 2017 · 106 citations

David Cohn
32 papers
David O'Malley
26 papers
Floor Backes
26 papers
Casey Cosgrove
25 papers · 17 as a fellow
Larry Copeland
23 papers
Christa Nagel
14 papers
Ritu Salani
12 papers
Jeffrey Fowler
11 papers
Paulina Haight
11 papers · 11 as a resident
Adrian Suarez
10 papers
David Barrington
9 papers · 9 as a resident
MV
Monica Vetter
9 papers · 6 as a fellow

Clinical trials

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Study chair · Recruiting
GOG Foundation
2022–2030
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034